贝伐珠单抗联合安罗替尼治疗非小细胞肺癌的临床疗效及对免疫状态的影响

doi:10.3969/j.issn.1001-8131.2024.01.013

Abstract
Figure/Table
References
Related Citation (14)

Download: PDF (550 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of bevacizumab combined with anlotinib in the treatment of non-small cell lung cancer（NSCLC）,and analyze its effect on immune status. Method A prospective randomized controlled study was conducted,selecting non-small cell lung cancer patients as the study subjects.The patients were divided into an observation group and a control group using a random number table method.The control group was treated with anlotinib,and the observation group was treated with anlotinib combined with bevacizumab.The clinical efficacy,T lymphocyte subsets（CD4+,CD3+,CD8+,CD4+/CD8+）,vascular endothelial growth factor（VEGF）level,KPS score,tumor marker level [serum carcinoembryonic antigen（CEA）,carbohydrate antigen 199（CA199）,CA125],survival time and adverse drug reactions were compared between the two groups. Results Before treatment,there was no statistical significant difference in various indicators between the two groups of patients（P>0.05）.After treatment,the disease control rate（DCR）,objective response rate（ORR）,CD4+,CD3+,CD4+/CD8+,and KPS scores of the observation group were significantly higher than those of the control group（P<0.05）.The levels of CD8+,VEGF,CEA,CA199,and CA125 in the observation group were lower than those in the control group（P<0.05）.Following up for 1 year,the median survival time of the observation group patients was 6 months,while the median survival time of the control group patients was 5 months.The total survival time of the observation group patients was significantly longer than that of the control group（lg rank=33.616,P<0.001）.There was no statistical significant difference in adverse reactions between the two groups（P>0.05）. Conclusion The combination of bevacizumab and anlotinib can improve the immune function and functional status of patients with non-small cell lung cancer,prolong the survival period,reduce the expression of tumor markers and VEGF,and has a good clinical effect.

Key words： Bevacizumab Anlotinib Non-small cell lung cancer Survival period Tumor markers

Received: 25 May 2023

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Ding Yanhua
	Men Shuai
	Zhang Jiangxia
	Zhang Xu
	Zhang Shancun
	Liu Lu
	Lv Hongwei
	Xiao Zhenghong

Cite this article:

Ding Yanhua,Men Shuai,Zhang Jiangxia, et al. Clinical Efficacy of Bevacizumab Combined with Anlotinib in The Treatment of Non-small Cell Lung Cancer and Its Influence on Immune Status[J]. journal1, 2024, 44(1): 41-44.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2024.01.013 OR http://www.hrbyybjb.org.cn/EN/Y2024/V44/I1/41

[1] 中国临床肿瘤学会血管靶向治疗专家委员会,中国临床肿瘤学会非小细胞肺癌专家委员会,中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组.晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2020版)[J].中华肿瘤杂志,2020,42(12):1063-1077.
[2] 孙如坤,刘岩,潘春香,等.手术切除肺腺癌患者免疫细胞浸润分析及预后关系[J].临床肺科杂志,2022,27(1):88-93.
[3] 李陶威,马天江,张耀勇,等.重组人血管内皮抑制素联合贝伐珠单抗治疗中晚期非小细胞肺癌的疗效及对血清CEA、CYFRA21-1和VEGF水平的影响[J].实用癌症杂志,2021,36(8):1309-1312.
[4] 段宏民,赵玉涛,陈楠,等.安罗替尼对肺腺癌细胞株A549放射敏感性的影响及机制[J].昆明医科大学学报,2021,42(8):40-46.
[5] 石远凯,孙燕.临床肿瘤内科手册[M].6版.北京:人民卫生出版社,2015:394.
[6] 杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90111.
[7] Friendler A H,Ettinger R L.Karnofsky performance status scale[J].Spec Care Dentist,2009,29(4):147-148.
[8] 张力,杨云鹏,中国抗癌协会肿瘤康复与姑息治疗专业委员会,等.恩沙替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌专家共识[J].中华肿瘤杂志,2022,44(4):297-306.
[9] 罗小桐,董信春,苟云久,等.紫杉醇+卡铂联合与不联合贝伐珠单抗治疗晚期非小细胞肺癌临床效果的系统评价与Meta分析[J].中国胸心血管外科临床杂志,2023,30(1):126-132.
[10] 冯霞,肖建,敬梅,等.奥希替尼联合贝伐珠单抗一线治疗EGFR敏感突变阳性晚期非小细胞肺癌的临床疗效观察[J].临床和实验医学杂志,2022,21(16):1697-1700.
[11] 蒋一玲,张传领,陈承,等.贝伐珠单抗联合靶向治疗对EGFR突变型非小细胞肺癌患者的疗效观察[J].中华全科医学,2021,19(8):1306-1309.
[12] 潘恩媛,夏琴.贝伐珠单抗联合化疗治疗非小细胞肺癌的效果及对T细胞亚群、免疫功能的影响[J].中国医药导报,2021,18(29):118-121.
[13] 朱爱红,吴云,钱娟,等.ADNEX模型联合ROMA指数、CA199鉴别卵巢肿瘤良恶性的临床价值及卵巢恶性肿瘤的影响因素分析[J].现代生物医学进展,2022,22(19):3670-3675.
[14] 汪淑映,罗飞,鲍瑜.miRNA-1260b、miRNA-182-5p及CEA、CA199表达水平对结直肠癌诊断的价值研究[J].临床和实验医学杂志,2022,21(13):1393-1397.